VOWST is the FIRST and ONLY orally administered microbiome therapeutic to prevent C. diff* recurrence^1,2

*Clostridioides difficile (C. diff) infection.

SUPERIOR PREVENTION OF C. DIFF RECURRENCE
COMPARED TO ANTIBIOTICS ALONE

Statistically significant reduction of C. diff recurrence ( P <0.001)^1-3

PROVEN EFFICACY
AT 8 WEEKS^1,2

ECOSPOR III
PRIMARY ENDPOINT

DURABLE RESPONSE
AT 24 WEEKS^1,3

ECOSPOR III
SECONDARY ENDPOINT

^† Calculated by the rate of C. diff recurrence, which was significantly lower in VOWST recipients compared to those receiving antibiotics alone—12% vs. 40%, respectively—a 0.32 relative risk (95% confidence interval, 0.18, 0.58; P <0.001).^1,2

^‡ Relative risk of 0.46 (95% CI, 0.30, 0.73).

ECOSPOR III was a Phase 3, multicenter, double-blind, randomized, placebo-controlled trial evaluating C. diff recurrence at 8 weeks; secondary endpoints at 4, 12, 24 weeks. In the intent-to-treat population, participants received standard-of-care antibiotics (vancomycin/fidaxomicin) and laxative followed by VOWST or placebo. Those lost to follow-up, terminated prematurely, or died prior to end of study time interval counted as a recurrence. Data were rounded to the nearest whole number for presentation.

VOWST WAS GENERALLY WELL TOLERATED THROUGH 8 WEEKS¹

The majority of adverse reactions were mild or moderate in severity¹

The most common adverse reactions (reported in ≥5% of VOWST-treated participants and at a rate greater than placebo) were abdominal distension (31%), fatigue (22%), constipation (14%), chills (11%), and diarrhea (10%)¹

No serious adverse events were considered related to the use of VOWST¹

Consider prescribing VOWST and antibiotics at the
same time to help ensure patients get access to
VOWST at the time of completing antibiotics

LEARN MORE ABOUT VOWST EFFICACY

See results from the Phase 3 clinical development program

DISCOVER THE DATA >

VOWST SAFETY
PROFILE

Incidence of most common adverse reactions compared to antibiotics alone

LEARN ABOUT SAFETY >

GET INFORMATION
ABOUT VOWST VOYAGE™

Helping your patients access their VOWST treatment

ENROLL PATIENTS >

REFERENCES: 1. VOWST [Prescribing Information]. Cambridge, MA: Seres Therapeutics, Inc. and Nestlé Health Science. 04/2023. 2. Feuerstadt P, Louie TJ, Lashner B, et al. N Engl J Med. 2022;236:220-229. doi:10.1056/NEJMoa2106516. 3. Cohen SH, Louie TJ, Sims M, et al. JAMA. Published Online: October 19, 2022. doi:10.1001/jama.2022.16476.

ECOSPOR III
Multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in adults (≥18 years) with recurrent C. diff ^1-3
Primary Endpoint • Recurrence at 8 weeks* Secondary Endpoints • Adverse events within 24 weeks • Recurrence at 4, 12, 24 weeks*
Recurrence confirmed with C. diff toxin test and ≥3 unformed bowel movements per day over 2 days*
10–21 days of vancomycin (125 mg QID) or fidaxomicin (200 mg BID)

ECOSPOR IV
Multicenter, open-label, single-arm trial in adults (≥18 years) with recurrent C. diff ⁵
Primary Endpoint Adverse events within 24 weeks Secondary Endpoints Recurrence at 4, 8, 12, 24 weeks
Recurrence confirmed with C. diff toxin test or PCR and ≥3 unformed bowel movements per day over 2 days^*
10–42 days of vancomycin or 10–25 days of fidaxomicin

HELP DEFEND YOUR PATIENTS FROM RECURRENCE WITH THE

SUPERIOR PREVENTION OF C. DIFF RECURRENCE COMPARED TO ANTIBIOTICS ALONE

VOWST WAS GENERALLY WELL TOLERATED THROUGH 8 WEEKS1

HELP DEFEND YOUR PATIENTS
FROM RECURRENCE WITH THE

SUPERIOR PREVENTION OF C. DIFF RECURRENCE
COMPARED TO ANTIBIOTICS ALONE

VOWST WAS GENERALLY WELL TOLERATED THROUGH 8 WEEKS¹